Scientific deep-dive
A Pill to Hold What the Injection Lost
Daily oral orforglipron maintained 79.3% of weight already lost against 37.6% on placebo at a year in people coming off semaglutide, and 74.7% against 49.2% after tirzepatide. The trial had no arm that stayed on the injection, which is the question people actually have.
Plenty of people would like to lose the weight on an injection and then hold it with something simpler. A phase 3b trial tested that handover: participants who had lost weight on injectable semaglutide or tirzepatide moved to daily oral orforglipron or to placebo. In those coming off semaglutide, the pill maintained 79.3% of the reduction against 37.6% on placebo at 52 weeks. In those coming off tirzepatide, the figures were 74.7% against 49.2%.[1]
The result
In the semaglutide group the estimated treatment difference was 41.7 percentage points, with a confidence interval from 24.4 to 59.0. That is a wide interval, but comfortably clear of zero. In the tirzepatide group the difference was 25.5 points. All key secondary endpoints were met. The commonest adverse events were gastrointestinal and mostly mild to moderate.[1]
The placebo figure deserves its own look. People who switched to nothing still held 37.6% (after semaglutide) or 49.2% (after tirzepatide) of what they had lost, at a year. That is a third data point, after the real-world discontinuation data and SURMOUNT-4’s placebo arm, against the popular account that stopping means regaining everything.
The comparison that was not run
There was no arm that stayed on the injection.
The authors name this limitation themselves.[1] It matters more than any figure in the trial, because it is the question people have. Nobody wonders whether a pill beats stopping; obviously it does. What they want to know is whether switching costs them anything against staying on what was working.
We have one adjacent answer. In SURMOUNT-MAINTAIN, people who stepped down to a lower injectable dose held less than those who stayed at full dose, and needed rescue therapy three times as often (25% against 8%; see the maintenance trial). Less drug held much of the loss, but measurably less of it. Whether a switch to an oral agent behaves the same way is untested.
Why an oral maintenance option matters commercially
The authors describe orforglipron as a potentially globally scalable option, and scalability is the point. Orforglipron is a small molecule rather than a peptide, so it can be manufactured at a scale injectable peptides cannot. Peptide manufacturing capacity is the constraint behind the shortages this register has tracked from the commercial end.
A world where the expensive, supply-constrained injectable does the losing and a manufacturable pill does the holding is a plausible answer to a real bottleneck. It is also a commercially convenient story. Watch whether the maintenance data ever gets a fair comparison against simply continuing.
Frequently Asked Questions
References
- 1.Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial Nature Medicine. 2026. PMID: 42120723.
Compare the sellers
Related research
Every Other Week: Stretching the Interval
Patients moved to every-other-week dosing after a plateau held their weight and body composition over 36 weeks. It is a case series with no control group, and it is the third of three different ways to use less drug.
5 min read
Elecoglipron: A Second Oral GLP-1 Pill in Phase 2
Weight reductions from 2.6% to 10.5% at 26 weeks depending on dose, against 0.6% on placebo. 93% completed the study but only 75% completed the assigned treatment.
5 min read
Five Clicks Instead of a Quarter Milligram
One in five people on the label's titration schedule quit because of gut side effects. On a slower schedule it was one in fifty, at the same final dose, with the same results.
7 min read
Can You Lower the Dose and Keep the Weight Off?
Stepping down to 5 mg held 16.6% of body weight lost against 21.9% for staying at the full dose. But rescue therapy went from 8% to 25%, and to 67% on placebo.
6 min read
Not Taking It and Not Tolerating It
Real-world studies usually measure adherence and stopping separately, with every kind of stopping counted the same way. That merges someone whose body cannot tolerate the drug with someone not taking it reliably. A Scottish study separated them and found different predictors.
6 min read
The Cardiovascular Cost of Stopping
A review argues that weight and blood sugar fluctuation are themselves cardiovascular risk factors, and that these drugs do not stabilize arteries the way statins do. It also says few data exist on hard outcomes after stopping.
5 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Gala
Moving between compounded and brand without changing seller
From $179/mo
Get started →Luvo Health
Moving between compounded and brand without changing seller
From $179/mo
Get started →Oak
A choice of compounded injections, oral semaglutide and brand-name GLP-1s from one cash-pay checkout
From $100/mo
Get started →